Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of radiation dose and field design with concurrent S-1 + cisplatin for locally advanced thoracic esophageal squamous cell carcinoma
ChiCTR-IPR-15007172Phase 3Completed
- Sponsor
- Shandong Cancer Hospital
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tegafur and cisplatin in Esophageal Squamous Cell Carcinoma (ESCC) (4 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: overall survival. Started Oct 2016; status: completed.
02
Drugs
tegafurcisplatin
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR-IPR-15007172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-15007172.